Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI. Faux NG, et al. Among authors: blennow k. J Alzheimers Dis. 2010;20(2):509-16. doi: 10.3233/JAD-2010-1390. J Alzheimers Dis. 2010. PMID: 20164561 Free article. Clinical Trial.
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease.
Ewers M, Schmitz S, Hansson O, Walsh C, Fitzpatrick A, Bennett D, Minthon L, Trojanowski JQ, Shaw LM, Faluyi YO, Vellas B, Dubois B, Blennow K, Buerger K, Teipel SJ, Weiner M, Hampel H; Alzheimer's Disease Neuroimaging Initiative. Ewers M, et al. Among authors: blennow k. Neurobiol Aging. 2012 Aug;33(8):1599-608. doi: 10.1016/j.neurobiolaging.2011.05.005. Epub 2011 Jun 17. Neurobiol Aging. 2012. PMID: 21684041 Free PMC article.
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.
Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Lladó A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K. Mattsson N, et al. Among authors: blennow k. Alzheimers Dement. 2011 Jul;7(4):386-395.e6. doi: 10.1016/j.jalz.2011.05.2243. Alzheimers Dement. 2011. PMID: 21784349 Free PMC article.
Predicting MCI outcome with clinically available MRI and CSF biomarkers.
Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK; Alzheimer's Disease Neuroimaging Initiative. Heister D, et al. Among authors: blennow k. Neurology. 2011 Oct 25;77(17):1619-28. doi: 10.1212/WNL.0b013e3182343314. Epub 2011 Oct 12. Neurology. 2011. PMID: 21998317 Free PMC article.
Lower CSF interleukin-6 predicts future depression in a population-based sample of older women followed for 17 years.
Kern S, Skoog I, Börjesson-Hanson A, Blennow K, Zetterberg H, Östling S, Kern J, Gudmundsson P, Marlow T, Rosengren L, Waern M. Kern S, et al. Among authors: blennow k. Brain Behav Immun. 2013 Aug;32:153-8. doi: 10.1016/j.bbi.2013.03.011. Epub 2013 Apr 9. Brain Behav Immun. 2013. Retraction in: Brain Behav Immun. 2014 Feb;36:216. doi: 10.1016/j.bbi.2013.11.011 PMID: 23583855 Retracted.
CSF biomarker variability in the Alzheimer's Association quality control program.
Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NH, Robin Hsiung GY, Hyman B, Iqbal K, Kaeser SA, Lachno DR, Lleó A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman RA, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K; Alzheimer's Association QC Program Work Group. Mattsson N, et al. Among authors: blennow k. Alzheimers Dement. 2013 May;9(3):251-61. doi: 10.1016/j.jalz.2013.01.010. Alzheimers Dement. 2013. PMID: 23622690 Free PMC article.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. Among authors: blennow k. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
2,221 results